BioTransplant, Inc.

kits for use in pig or human to human organ transplants comprising one or more of the following components - porcine bone marrow cells; myelosuppressive agents; antibodies to deplete organ transplant recipient's T cells and NK cells; cytokines; gene therapy vector, namely, a carrier molecule for expressing a gene; human bone marrow cells; and human organs

pharmaceutical preparations, namely, antibody for use in organ transplants

pharmaceutical preparations, namely, antibody for use in organ transplants

kits for use in human to human organ transplants comprising one or more of the following components - myelosuppressive agents; antibodies to deplete organ transplant recipient's T cells and NK cells; cytokines; gene therapy vector, namely, a carrier molecule for expressing a gene; human bone marrow cells; and human organs

kits for use in pig or human to human organ transplants comprising one or more of the following components - porcine bone marrow cells; myelosuppressive agents; antibodies to deplete organ transplant recipient's T cells and NK cells; cytokines; gene therapy vector, namely, a carrier molecule for expressing a gene; porcine organ; pharmaceutical preparations, namely, an antibody for use in organ transplants; human bone marrow cells; and human organs

kits for use in pig to human organ transplants comprising one or more of the following components - porcine bone marrow cells; myelosuppressive agents; antibodies to deplete organ transplant recipient's T cells and NK cells; cytokines; gene therapy vector, namely, a carrier molecule for expressing a gene; and porcine organs

pharmaceutical preparations for use in studying successive organ transplants from humans to humans

pharmaceutical preparations for use in studying successive organ transplants

pharmaceutical preparations for use in studying successive organ transplants

pharmaceutical preparations for use in studying successive organ transplants from pigs to humans